Glipizide Dosing Recommendations
Start glipizide at 5 mg once daily before breakfast for most patients, but reduce to 2.5 mg once daily in elderly patients, those with liver disease, or those with renal impairment (eGFR 30-44 mL/min/1.73 m²). 1
Starting Dose
- Standard patients: 5 mg once daily before breakfast 1
- Elderly, hepatic impairment, or mild renal impairment: 2.5 mg once daily 1
- Timing: Administer approximately 30 minutes before breakfast to achieve greatest reduction in postprandial hyperglycemia 1
Titration Schedule
Increase dose in increments of 2.5-5 mg based on blood glucose response, with at least several days between adjustments. 1
- Maximum once-daily dose: 15 mg 1
- Doses above 15 mg should be divided and given before meals 1
- Maximum total daily dose: 40 mg 1
Critical Caveat on Dose Escalation
Do not exceed 20 mg daily for glipizide immediate-release, as higher doses provide minimal additional glycemic benefit and may actually reduce beta-cell function. Research demonstrates that increasing glipizide from 10 mg to 40 mg daily produces negligible improvement in HbA1c (9.6% vs 8.9%) while paradoxically weakening insulin response to meals 2. The pharmacodynamic data shows maximal efficacy at 20 mg for fasting glucose and 5 mg for HbA1c 3.
Special Population Adjustments
Renal Impairment
For patients with eGFR 30-44 mL/min/1.73 m² (Stage 3b CKD): Initiate conservatively at 2.5 mg once daily and titrate slowly to avoid hypoglycemia. 4
- Glipizide is preferred over glyburide in renal impairment, as glyburide is not recommended 4
- Conservative dosing is essential due to increased hypoglycemia risk 1
Elderly Patients
Start at 2.5 mg once daily in geriatric patients regardless of renal function. 1
The elderly face significantly higher hypoglycemia risk with sulfonylureas. Studies show that despite few patient-reported hypoglycemic episodes, ambulatory glucose monitoring reveals a high incidence of readings <4.5 mmol/L in elderly patients on both glipizide and glyburide 5. This underscores the need for:
- Conservative initial dosing 1
- Close surveillance with home glucose monitoring 5
- Intensive patient education about hypoglycemia risks 5
Maintenance Dosing
- Some patients achieve control on once-daily dosing; others require divided doses 1
- Doses above 15 mg should ordinarily be divided 1
- Doses above 30 mg can be safely given twice daily in long-term patients 1
Important Clinical Considerations
Hypoglycemia Risk
Sulfonylureas carry substantial hypoglycemia risk in elderly and renally impaired patients, requiring conservative dosing and close monitoring. The ADA/KDIGO consensus emphasizes that glipizide should be "initiated conservatively and titrated slowly to avoid hypoglycemia" in these populations 4.
Drug Interactions
Administer glipizide at least 4 hours before colesevelam, as coadministration reduces glipizide exposure 1.
Monitoring Requirements
- Monitor blood glucose periodically to determine minimum effective dose 1
- Check for primary failure (inadequate response at maximum dose) 1
- Check for secondary failure (loss of response after initial effectiveness) 1
- Glycosylated hemoglobin monitoring is valuable 1